Longview Innovation

We’re very excited by Dr. Rohit Khanna's appointment to the Board of our portfolio company, MOBILion Systems, Inc. Dr. Khanna adds extensive experience and connectivity across the #analyticalinstrumentation industry and strengthens MOBILion’s #strategicleadership at a critical time in their development. Welcome to the team. We’re looking forward to working with you. #hardscience #separationscience #analytics #pioneers Michael Burychka, Jason Smith, Dimitri Galitzine, Alessandro Levi

Well done on the Stitch3D partnership Exyn Technologies team. The collaboration takes their transformative #mapping technology, #ExynNexys, to the next level,?making the analysis, management, and sharing of high-quality 3D models streamlined for customers. #hardscienceinvesting #drones #roboticautonomy #data

We are delighted to share that our #Founder and #CEO, Michael Burychka, will be receiving the #NucleusAward2024 for excellence in #innovation and #STEM equity – for Longview’s contributions to Philadelphia’s innovation ecosystem. Michael has a deep passion for the #Philadelphia region and its potential to drive the innovation #economy, and we are proud that he and Longview have been recognized for their commitment to #science and the potential of the region. ? Please join us on September 24 to connect, network, and celebrate. You can register here: https://lnkd.in/gtXbHxx. Hope to see you there. University City Science Center

Great news from Carisma Therapeutics, which is moving forward with?its first #drugdevelopment candidate under its?partnership with Moderna. The candidate,?an experimental #celltherapy that targets the most prevalent type of #livercancer, triggers a $2 million payment from Moderna. This is a major step forward in the development of #immunotherapies for #solidtumors. Carisma is on a roll, and we’re excited by the momentum. www.longviewinnovation.com #hardscience #innovation #biotech #lifesciences #cancer #cancertreatment

Exyn Technologies lands its first #US-based partner,?Keystone Precision Solutions, to deliver its ground-breaking #autonomy and #mapping payload to the US market. This is another great step forward for Exyn. Congrats to Brandon Torres Declet and the whole team at Exyn. #drones #data #innovation #hardscience

Thrilling news from our portfolio company, Carisma Therapeutics! The FDA has granted Fast Track designation for its CT-0525 #cancer therapy, a promising development in the treatment of #solidtumors. This recognition underscores the potential of CT-0525 to address the critical #medical need of treating life-threatening malignancies. #cancertreatment #fasttrack #innovation #biotechnology #hardscience

Great article highlighting the transformative technology of our portfolio company, EnaChip Inc. They are revolutionizing power applications for #integratedcircuits - greatly reducing size and increasing power - to enable?new classes of #electronic products. We’re excited by the prospects and opportunities that lie ahead for EnaChip. #hardscience #semiconductors #microchips #innovation #technology

We’re delighted to see these words from #Philadelphia #Mayor Cherelle Parker thanking our portfolio company Exyn Technologies for building their business in the city. We feel the same way about the value of Philadelphia and the surrounding area as a center for innovation. We recognized early on the potential of so many great businesses, creating game-changing technologies here - like MOBILion Systems, Inc. and Carisma Therapeutics, who like Exyn we have supported from the very beginning and are changing the game in their industries. We’re excited to see them continue their journey and for the new companies that follow in their footsteps. #hardscience #innovation #investment #venture #earlystage #science

Amazing that our portfolio company Exyn Technologies has been included in Mining Digital’s 10 trends shaping the future of #mining article - confirming our belief in their #transformative #technology. Congrats to the entire team at Exyn. Keep up the great work. #3DMapping #ExynNexys #autonomusrobotics #data Brandon Torres Declet, Dimitri Galitzine

An exciting first for Carisma Therapeutics. First patient dosed?in the CT-0525 #Phase1 trial -?a significant step in the development of engineered #myeloidcells. And it marks?the first time a #CARMonocyte is tested in humans for the treatment of #solidtumors.?This next-generation approach has the potential to have a greater impact on patient #treatment than the initial CAR-Macrophage program. We’re very excited to see how this trial progresses. #lifesciences #biotechnology #ventureinvesting #cancer #cancertreatment #innovation Jason Smith